Meine Zukunft Innovative Chemie Interviews Inspirierende Job-Links Meine Ausbildung

BIOCRATES Life Sciences AG

Firmenlogo

Biocrates is a leading metabolomics company using a mass-spectrometry based technology platform. Its products and services extract, deliver, and present rich information residing in metabolite networks with unprecedented speed, low cost, and high confidence. Biocrates’ quantitative approach enables immediate identification of metabolites, measurement of their absolute concentrations, and mapping to their respective pathways.

AbsoluteIDQ™ Kit
The AbsoluteIDQ™ p150 Kit is used in combination with an existing mass spectrometer, allowing customers to keep their proprietary data in-house. They can accurately measure and identify more than 160 metabolites in 4 compound classes from their valuable clinical and pre-clinical samples in just minutes per sample. MetIQ™ software package is an integral part of the AbsoluteIDQ™ Kit and provides a solution for the complete analytical process of targeted metabolomics, from project setup to calculation of metabolite concentrations.

TargetIDQ™ Services
Biocrates works in collaboration with its partners to deliver the most trusted targeted metabolomics information in the industry. Biocrates’ has extensive experience in metabolomics method development, R&D, bioinformatics software, analytics, and data interpretation. TargetIDQ™ Services provide customers direct access to Biocrates’ trusted expertise, enabling identification and quantification of hundreds of metabolites from a broad range of samples, ultimately revealing meaningful biomarkers.

News Focussing on Members

(AVIR Green Hills Biotechnology AG) deltaFLU –innovative vaccines for intranasal spray delivery or oral administration more 

 

(Apeptico) APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory Failure  more 

 

(Intercell) Intercell announces new management structure more 

 

(Eucodis) EUCODIS Bioscience and evocatal enter into alliance more 

 

(Intercell) Staph Bakali new Chief Business Officer more 

 

(Intercell) Intercell acquires antibody technology platform to further exploit its capabilities to combat infectious diseases more 

 

(Apeptico) APEPTICO granted Orphan Drug Designation by FDA for development compound AP301 more